Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology
08 janv. 2020 08h00 HE
|
Pfenex, Inc.
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization...
Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
18 déc. 2019 08h00 HE
|
Pfenex, Inc.
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with...
Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference
20 nov. 2019 16h10 HE
|
Pfenex, Inc.
SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
Pfenex to Present at the Evercore ISI HealthCONx Conference 2019
19 nov. 2019 16h10 HE
|
Pfenex, Inc.
SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
Pfenex Announces Management Change
13 nov. 2019 16h40 HE
|
Pfenex, Inc.
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief...
Pfenex Reports Third Quarter 2019 Results and Provides Business Update
07 nov. 2019 16h05 HE
|
Pfenex, Inc.
Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the...
Pfenex to Present at the Jefferies 2019 London Healthcare Conference
06 nov. 2019 16h10 HE
|
Pfenex, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies...
Pfenex to Announce Third Quarter 2019 Financial Results on November 7th
24 oct. 2019 16h30 HE
|
Pfenex, Inc.
SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study
14 oct. 2019 08h00 HE
|
Pfenex, Inc.
Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks Pfenex believes the study...
Pfenex Provides Update for PF708 Outside the United States
11 oct. 2019 08h00 HE
|
Pfenex, Inc.
New Exclusive Commercialization Agreements in South Korea, Canada, and Israel Submission of Marketing Authorization Application for PF708 in Saudi Arabia Potential approval of PF708 in the EU as...